Brief: Regenxbio Announces FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II
18/08/2025 23:13
Aug 18 (Reuters) - Regenxbio Inc RGNX.O: REGENXBIO ANNOUNCES FDA REVIEW EXTENSION OF BLA FOR RGX-121 TO TREAT PATIENTS WITH MPS II REGENXBIO INC - PDUFA DATE EXTENDED TO FEBRUARY 8, 2026 Source text: ID:nPn5DTxK3a Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))